Latest research on Rabeprazole

Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.

Latest findings

CYP2C19 inhibitors included Omeprazole and esOmeprazole, and CYP2C19 non-inhibitors included dexlansoprazole, lansoprazole, Pantoprazole, and Rabeprazole [18,19]. [source, 2016]
HP was eradicated with 400 mg of CLARITHROMYCIN, 1,500 mg of Amoxicillin hydrate, and 20 mg of Rabeprazole per day for 7 days. [source, 2016]
Participants with GERD symptoms were treated with a standard dose of PPIs (eg, esomeprazole, Rabeprazole, Pantoprazole, omeprazole, and Lansoprazole), and symptoms were re-assessed after four weeks of treatment. [source, 2015]
Serum Magnesium concentrations were similar in patients taking the PPI Omeprazole (1.86±0.24 mg/dL), Lansoprazole (1.86±0.17 mg/dL) and Rabeprazole (1.86±0.20 mg/dL; table 3). [source, 2015]
In brief, a 20-mg oral dose of Omeprazole was considered to have an equivalent therapeutic efficacy to 20 mg esOmeprazole, 30 mg Lansoprazole, 40 mg Pantoprazole, and 20 mg Rabeprazole. [source, 2015]
Rabeprazole, a PPI developed by Eisai Co., Ltd., exerts a rapid and potent inhibitory effect on gastric acid secretion. [source, 2015]
Long-term use of Rabeprazole was confirmed to be safe in studies of two to five-year maintenance therapy for GERD. [source, 2015]
Rabeprazole was recently found to reduce the incidence of esophageal and gastroduodenal mucosal injury due to LDA therapy in healthy volunteers. [source, 2015]
Our recent 24-week, double-blind, comparative study (PLANETARIUM study) with a mucosal protective agent as the control showed that Rabeprazole (10 and 5 mg) was effective and safe in the prevention of peptic ulcer recurrence in LDA users (the cumulative recurrence rate of peptic ulcers at 24 weeks was 1.4% in the Rabeprazole 10-mg group, 2.8% in the Rabeprazole 5-mg group and 21.7% in the teprenone group). [source, 2015]
( Long-term Japanese data over more than one year are available for the similar PPIs, Lansoprazole and esomeprazole,( but the data for Rabeprazole extended only to 24 weeks. [source, 2015]